KEGG   DRUG: Palifermin
Entry
D05338                      Drug                                   
Name
Palifermin (USAN/INN);
Kepivance (TN)
Product
KEPIVANCE (Swedish Orphan Biovitrum AB (publ))
Formula
C729H1156N204O207S10
Exact mass
16400.3409
Mol weight
16410.8715
Sequence
MSYDYMEGGD IRVRRLFCRT QWYLRIDKRG KVKGTQEMKN NYNIMEIRTV AVGIVAIKGV
ESEFYLAMNK EGKLYAKKEC NEDCNFKELI LENHYNTYAS AKWTHNGGEM FVALNQKGIP
VRGKKTKKEQ KTAHFLPMAI T
  Type
Peptide
Remark
ATC code: V03AF08
Product: D05338<US>
Efficacy
Anti-inflammatory (oral)
Comment
Treatment of mucositis, Keratinocyte growth factor (KGF)
Target
FGFR2 (CD332) [HSA:2263] [KO:K05093]
  Pathway
hsa04550  Signaling pathways regulating pluripotency of stem cells
hsa04810  Regulation of actin cytoskeleton
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 V VARIOUS
  V03 ALL OTHER THERAPEUTIC PRODUCTS
   V03A ALL OTHER THERAPEUTIC PRODUCTS
    V03AF Detoxifying agents for antineoplastic treatment
     V03AF08 Palifermin
      D05338  Palifermin (USAN/INN) <US>
USP drug classification [BR:br08302]
 Antineoplastics
  Antineoplastic Adjuncts/Mitigators
   Palifermin
    D05338  Palifermin (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   FGFR family
    FGFR2 (CD332)
     D05338  Palifermin (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D05338
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D05338
Other DBs
CAS: 162394-19-6
PubChem: 47207024
NIKKAJI: J2.317.269K
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system